Zobrazeno 1 - 10 of 39 pro vyhledávání: '"Toshihisa, Tomoda"'
1
Akademický článek
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
Autor: Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Kenichi Harada, Motonobu Nakamura, Naohiro Fujimoto
Publikováno v: Current Oncology, Vol 31, Iss 2, Pp 862-871 (2024)
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. He
Externí odkaz: https://doaj.org/article/090e7c2b79cf474b85e1f11873b1d392
Zobrazit plný text záznamu
2
Akademický článek
Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
Autor: Takashi Matsumoto, Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto
Publikováno v: Prostate International, Vol 9, Iss 2, Pp 96-100 (2021)
Background: There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed the efficacy and safety of CBZ chemotherapy in patients with CRPC aged 75 years o
Externí odkaz: https://doaj.org/article/f27102a2ae634af5bf029056276fdfab
Zobrazit plný text záznamu
3
Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Autor: Takahito Negishi, Tohru Nakagawa, Naotaka Nishiyama, Hiroshi Kitamura, Eijiro Okajima, Nobuki Furubayashi, Yoshifumi Hori, Kentarou Kuroiwa, Yuhyon Son, Narihito Seki, Toshihisa Tomoda, Motonobu Nakamura
Publikováno v: Japanese Journal of Clinical Oncology. 52:1430-1435
Introduction Metastases from renal cell carcinoma develop in various organs. However, the breadth of discrepancy in response to immune checkpoint inhibitors across tumor sites within the same individual remains unclear. Patients and methods We review
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b9f11fb4a7ab9c938472a0090f084a
https://doi.org/10.1093/jjco/hyac144
Zobrazit plný text záznamu
4
Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study
Autor: Nobuki, Furubayashi, Futoshi, Morokuma, Toshihisa, Tomoda, Yoshifumi, Hori, Takahito, Negishi, Akihiro, Miura, Hiroki, Komori, Kentaro, Kuroiwa, Motonobu, Nakamura
Publikováno v: Anticancer Research. 42:1571-1577
The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear.Thirty-four patients who received pembrolizumab as second-line treatment after first-line platinum-b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b507b1f1908827c6a1bf43e3163ef1
https://doi.org/10.21873/anticanres.15631
Zobrazit plný text záznamu
5
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
Autor: Motonobu Nakamura, Naotaka Sakamoto, Narihito Seki, Nobuki Furubayashi, Toshihisa Tomoda, YooHyun Song, Yoshifumi Hori, Kentaro Kuroiwa, Shingo Tamura, Akinori Minato, Takahito Negishi, Naohiro Fujimoto
Publikováno v: Cancer Management and Research
Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Shingo Tamura,7 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonobu Nakamura1 1Department of Urology, National Ho
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500ce6b05fc6f03552cda80e7da5c04a
https://doi.org/10.2147/cmar.s333823
Zobrazit plný text záznamu
7
Site-specific Response to Nivolumab in Renal Cell Carcinoma
Autor: Eijiro Okajima, Motonobu Nakamura, Naotaka Nishiyama, Narihito Seki, Yoshifumi Hori, Nobuki Furubayashi, Tohru Nakagawa, Kentarou Kuroiwa, Toshihisa Tomoda, Takahito Negishi, Hiroshi Kitamura, Yuhyon Son
Publikováno v: Anticancer Research. 41:1539-1545
Background/aim Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. Pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e42825f1cf6fedcc1ff03ac307d37f
https://doi.org/10.21873/anticanres.14913
Zobrazit plný text záznamu
8
Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
Autor: Masatoshi Kumagai, Nobuki Furubayashi, Toshihisa Tomoda, Yoshifumi Hori, Noriaki Tokuda, Motonobu Nakamura, Futoshi Morokuma, Tomohiro Inoue, Takahito Negishi, Kentaro Kuroiwa
Publikováno v: Journal of Clinical Medicine Research
Background: Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYN
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa406f68a7b293a2b893a52ec40d2a1
https://doi.org/10.14740/jocmr4162
Zobrazit plný text záznamu
9
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
Autor: Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Yoshifumi Hori, Toshihisa Tomoda, Mirii Harada, Shingo Tamura, Akihiro Miura, Hiroki Komori, Kentaro Kuroiwa, Narihito Seki, Naohiro Fujimoto, Motonobu Nakamura
Publikováno v: Cancer management and research. 14
Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Mirii Harada,2 Shingo Tamura,7 Akihiro Miura,1 Hiroki Komori,1 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonob
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97caf2b0313fa5575c9bb92577fb746d
https://pubmed.ncbi.nlm.nih.gov/35535266
Zobrazit plný text záznamu
10
External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
Autor: Leandro, Blas, Masaki, Shiota, Motonobu, Nakamura, Akira, Yokomizo, Toshihisa, Tomoda, Naotaka, Sakamoto, Narihito, Seki, Shuji, Hasegawa, Takakazu, Yunoki, Masahiko, Harano, Kentaro, Kuroiwa, Masatoshi, Eto
Publikováno v: JMA journal. 5(2)
The Halabi model predicts the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with second-line therapy after docetaxel. We aimed to validate this model externally with an independent cohort, outs
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a5a76d8d50da4ae23cc5ad050265946b
https://pubmed.ncbi.nlm.nih.gov/35611227
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje